Abstract
This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m² of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months. A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFR mutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no significant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 mont...Continue Reading
References
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Nov 1, 2005·Lancet·Nick ThatcherKevin Carroll
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramaswamy GovindanJay Piccirillo
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Riichiroh MaruyamaMasahiro Fukuoka
Nov 26, 2008·Lancet·Edward S KimJean-Yves Douillard
Feb 18, 2009·The Oncologist·Giorgio ScagliottiFrances A Shepherd
Sep 22, 2009·Lancet·Tudor CiuleanuChandra P Belani
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher G AzzoliUNKNOWN American Society of Clinical Oncology
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardEdward S Kim
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher G AzzoliUNKNOWN American Society of Clinical Oncology
Jan 27, 2012·The Lancet Oncology·Tudor CiuleanuEmilio Esteban Gonzalez
Jun 8, 2012·Cancer·Jong-Mu SunUNKNOWN Korean Cancer Study Group
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 19, 2013·Journal of the National Cancer Institute·Chee Khoon LeeJames Chih-Hsin Yang
Apr 25, 2013·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyu-Won JungJin-Soo Lee
May 11, 2013·Cancer·Athanasios KarampeazisVassilis Georgoulias
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis G Paz-AresCesare Gridelli
Jul 26, 2013·The Lancet Oncology·Marina Chiara GarassinoUNKNOWN TAILOR trialists
May 21, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomoya KawaguchiAkihito Kubo
Citations
Jan 18, 2018·The Cochrane Database of Systematic Reviews·Esther Ha SimKwun M Fong
Mar 1, 2017·Frontiers in Medicine·Jens Köhler
Mar 25, 2021·Critical Reviews in Oncology/hematology·Yi ZhaoJianxing He